Better Therapeutics (NASDAQ:BTTX – Get Free Report) is anticipated to announce its resultson Thursday, August 13th. Analysts expect the company to post earnings of ($0.21) per share and revenue of $6.58 million for the quarter.
Better Therapeutics Price Performance
BTTX stock opened at $0.00 on Thursday. The company has a market capitalization of $4,058.00, a PE ratio of -0.00 and a beta of 0.87. Better Therapeutics has a twelve month low of $0.00 and a twelve month high of $0.00.
Better Therapeutics Company Profile
Better Therapeutics, Inc is a clinical-stage digital therapeutics company focused on developing prescription software-based treatments for cardiometabolic diseases. Its lead product candidate, BT-001, is a behavior-change program delivered via a smartphone application, designed to address underlying drivers of type 2 diabetes and hypertension through cognitive behavioral therapy techniques. The company’s platform is built to engage patients in personalized lifestyle modification, leveraging real-time feedback and data analytics to support sustained clinical improvements.
BT-001 is being evaluated in pivotal clinical trials under FDA investigational device exemptions, with studies examining its impact on glycemic control and blood pressure reduction.
Featured Stories
- Five stocks we like better than Better Therapeutics
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
